Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
2,266
Total Claims
$6.9M
Drug Cost
339
Beneficiaries
$20K
Cost/Patient
Risk Score Breakdown 14/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
-39%
Opioid rate vs peers
3.8% vs 6.3% avg
+50%
Cost per patient vs peers
$20K vs $14K avg
Opioid Prescribing
3.8%
Opioid Rate
87
Opioid Claims
$1,816
Opioid Cost
21.8%
Long-Acting Rate
Brand vs Generic
Brand: 0 claims · $0
Generic: 1,691 claims · $360K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apalutamide | 82 | $1.3M |
| Acalabrutinib Maleate | 73 | $1.1M |
| Lenalidomide | 33 | $723K |
| Ibrutinib | 34 | $515K |
| Cabozantinib S-Malate | 14 | $375K |
| Dasatinib | 27 | $347K |
| Ruxolitinib Phosphate | 21 | $330K |
| Pomalidomide | 12 | $275K |
| Niraparib Tosylate | 13 | $252K |
| Lenalidomide | 13 | $206K |
| Fedratinib Dihydrochloride | 12 | $158K |
| Sunitinib Malate | 14 | $88K |
| Apixaban | 85 | $54K |
| Rivaroxaban | 22 | $14K |
| Imatinib Mesylate | 19 | $4,004 |
Prescribing Profile
Patient Profile
73
Avg Age
59%
Female
2.18
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data